These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39110987)

  • 1. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
    Hoff FW; Blum WG; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Archer KJ; Patel PA; Collins RH; Baer MR; Duong VH; Arellano ML; Stock W; Odenike O; Redner RL; Kovacsovics T; Deininger MW; Zeidner JF; Olin RL; Smith CC; Foran JM; Schiller GJ; Curran EK; Koenig KL; Heerema NA; Chen T; Martycz M; Stefanos M; Marcus SG; Rosenberg L; Druker BJ; Levine RL; Burd A; Yocum AO; Borate UM; Mims AS; Byrd JC; Madanat YF
    Blood Adv; 2024 Oct; 8(20):5297-5305. PubMed ID: 39110987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
    Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
    Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
    Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
    Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
    Rausch C; Rothenberg-Thurley M; Dufour A; Schneider S; Gittinger H; Sauerland C; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; von Bergwelt-Baildon M; Spiekermann K; Herold T; Metzeler KH
    Leukemia; 2023 Jun; 37(6):1234-1244. PubMed ID: 37041198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
    Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
    Herold T; Rothenberg-Thurley M; Grunwald VV; Janke H; Goerlich D; Sauerland MC; Konstandin NP; Dufour A; Schneider S; Neusser M; Ksienzyk B; Greif PA; Subklewe M; Faldum A; Bohlander SK; Braess J; Wörmann B; Krug U; Berdel WE; Hiddemann W; Spiekermann K; Metzeler KH
    Leukemia; 2020 Dec; 34(12):3161-3172. PubMed ID: 32231256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine.
    Kim M; Ahn SY; Kim T; Jung SH; Song GY; Yang DH; Lee JJ; Kim MY; Park JH; Shin MG; Ahn JS; Kim HJ; Kim DDH
    Hematology; 2024 Dec; 29(1):2324417. PubMed ID: 38433437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
    Lachowiez CA; Long N; Saultz J; Gandhi A; Newell LF; Hayes-Lattin B; Maziarz RT; Leonard J; Bottomly D; McWeeney S; Dunlap J; Press R; Meyers G; Swords R; Cook RJ; Tyner JW; Druker BJ; Traer E
    Blood Adv; 2023 May; 7(9):1899-1909. PubMed ID: 36441905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
    Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
    Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
    Song GY; Kim HJ; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Kim MY; Cheong JW; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Choi CK; Kim HJ; Ahn JS; Kim DDH
    Sci Rep; 2024 Apr; 14(1):8517. PubMed ID: 38609396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Mohty R; Massoud R; Chakhachiro Z; Mahfouz R; Nassif S; El-Cheikh J; Bazarbachi A; Abou Dalle I
    Leuk Res; 2021 Jun; 105():106568. PubMed ID: 33857784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
    Gangat N; Karrar O; Iftikhar M; McCullough K; Johnson IM; Abdelmagid M; Abdallah M; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Saliba AN; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A
    Am J Hematol; 2024 Feb; 99(2):193-202. PubMed ID: 38071734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
    Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
    Keren-Froim N; Heering G; Sharvit G; Zlotnik M; Nagler A; Shimoni A; Avigdor A; Canaani J
    Ann Hematol; 2022 Feb; 101(2):309-316. PubMed ID: 34989829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.
    Gross S; Ihlow J; Busack L; Adamiak K; Schrezenmeier J; Jesse J; Schwarz M; Flörcken A; Vuong LG; Rieger K; Krönke J; le Coutre P; Boldt V; von Brünneck AC; Horst D; Burmeister T; Blau IW; Keller U; Bullinger L; Westermann J
    Blood Cancer J; 2024 Sep; 14(1):160. PubMed ID: 39284846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.
    Datoguia TS; Velloso EDRP; Helman R; Musacchio JG; Salvino MA; Soares RA; Higashi M; Fadel AV; E Silva RSA; Hamerschlak N; Santos FPS; Campregher PV
    Med Oncol; 2018 Sep; 35(11):141. PubMed ID: 30187210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.